Anti-Elastin Antibody Targeting for Degraded Fiber Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Systemic delivery of therapeutic and diagnostic compounds for pathologies involving elastic fiber degradation is inefficient and often causes off-target effects due to first-pass filtration, requiring high doses and leading to toxic side effects.
Innovation Solution
Development of anti-elastin antibodies that specifically recognize and bind to degraded elastin epitopes, allowing targeted delivery of biologically active agents to affected areas using nanoparticles or other delivery mechanisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic delivery methods are used for therapeutic and diagnostic compounds, then the compounds can be delivered to affected areas, but the body filters the compounds via first-pass effect requiring large doses which cause toxic side effects
Solution Approach 1:
The patent uses anti-elastin antibodies as intermediary molecules that mediate the delivery of therapeutic and diagnostic compounds to degraded elastic fibers. The antibodies serve as carriers that specifically bind to elastin epitopes, enabling targeted delivery while avoiding systemic filtration and reducing toxic side effects through localized action at the disease site
2Reliability
If systemic delivery methods are used, then compounds can reach affected areas, but large doses are required which add to costs
Solution Approach 1:
The patent implements local quality by creating targeted delivery to specific locations where degraded elastic fibers are present. The anti-elastin antibodies ensure that therapeutic compounds are delivered locally to the disease site rather than systemically throughout the body, reducing the total dose amount required while maintaining effective treatment through localized concentration
3Reliability
If systemic delivery methods are used, then compounds can be administered, but off-target effects occur which alter normal tissue function
Solution Approach 1:
The anti-elastin antibodies act as specific intermediaries that guide therapeutic compounds to their exact target - degraded elastic fibers. This intermediary mechanism ensures that compounds do not distribute systemically but are instead directed precisely to the disease site, eliminating off-target effects while maintaining delivery capability
Solution Approach 2:
The invention achieves local quality by confining therapeutic action to specific regions where elastin degradation occurs. The antibody-mediated targeting ensures that only the affected tissues receive and respond to the therapeutic compounds, while normal tissues are spared from off-target effects and functional alterations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables precise delivery of therapeutic and diagnostic agents to connective tissues with minimal off-target effects, enhancing treatment efficacy and diagnostic accuracy while reducing systemic toxicity.
Implementation Method 1
an anti-elastin antibody or antigen binding portion thereof that specifically recognizes and binds an epitope elastin
Data Source
AI summary
Antibodies and antigen binding fragments thereof that specifically recognize and bind an epitope of elastin that is exposed and accessible in degraded elastic fiber are described. The antibodies and/or antigen binding fragments can be operably linked to a secondary component, including biologically active agents such as therapeutics and/or imaging agents. Optionally, the antibodies and/or antigen binding fragments thereof can be attached to a surface of a carrier, such as a particle, for specific binding and delivery of the carried agents to degraded elastic fiber.